These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11904355)

  • 21. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hyperphosphatemia and cardiovascular risk in patients on dialysis].
    Basić-Jukić N; Kes P
    Acta Med Croatica; 2004; 58(3):207-13. PubMed ID: 15503684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients.
    Canavese C; Bergamo D; Ciccone G; Longo F; Fop F; Thea A; Martina G; Piga A
    Kidney Int; 2004 Mar; 65(3):1091-8. PubMed ID: 14871430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron status and cardiovascular risk factors in patients with haemodialysis versus patients with ischaemic heart disease.
    Cheng YC; Kuo WW; Wu CH; Shu WT; Kuo CH; Hwang JM; Hsu HH; Chen LM; Huang CY; Lee SD
    Nephrology (Carlton); 2009 Feb; 14(1):65-9. PubMed ID: 19054334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysregulation of iron metabolism in cardiovascular diseases: From iron deficiency to iron overload.
    Bi Y; Ajoolabady A; Demillard LJ; Yu W; Hilaire ML; Zhang Y; Ren J
    Biochem Pharmacol; 2021 Aug; 190():114661. PubMed ID: 34157296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up.
    Bayés B; Pastor MC; Bonal J; Foraster A; Romero R
    Nephrol Dial Transplant; 2006 Apr; 21(4):984-90. PubMed ID: 16326744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
    Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
    Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.
    Rostoker G; Vaziri ND; Fishbane S
    Drugs; 2016 May; 76(7):741-57. PubMed ID: 27091216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular disease in peritoneal dialysis patients.
    Fassett RG; Driver R; Healy H; Coombes JS
    Panminerva Med; 2009 Sep; 51(3):151-61. PubMed ID: 19859050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution.
    Rostoker G; Vaziri ND
    Hemodial Int; 2017 Jun; 21 Suppl 1():S68-S77. PubMed ID: 28332306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular calcification in end-stage renal disease.
    Salusky IB; Goodman WG
    Nephrol Dial Transplant; 2002 Feb; 17(2):336-9. PubMed ID: 11812902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Safety of parenteral iron therapy].
    Kessler M
    Nephrol Ther; 2006 Nov; 2 Suppl 5():S350-5. PubMed ID: 17373283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.
    Kalantar-Zadeh K; Don BR; Rodriguez RA; Humphreys MH
    Am J Kidney Dis; 2001 Mar; 37(3):564-72. PubMed ID: 11228181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.
    Locatelli F; Canaud B; Eckardt KU; Stenvinkel P; Wanner C; Zoccali C
    Nephrol Dial Transplant; 2003 Jul; 18(7):1272-80. PubMed ID: 12808161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Increased iron store and its relationship with cardiovascular disease].
    Meroño T; Sorroche P; Brites FD
    Medicina (B Aires); 2011; 71(6):566-72. PubMed ID: 22167735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Macdougall IC; Bircher AJ; Eckardt KU; Obrador GT; Pollock CA; Stenvinkel P; Swinkels DW; Wanner C; Weiss G; Chertow GM;
    Kidney Int; 2016 Jan; 89(1):28-39. PubMed ID: 26759045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
    Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
    Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron overload in the erythropoietin era.
    Robbins KC
    Nephrol Nurs J; 2000 Apr; 27(2):227-31. PubMed ID: 11111550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PREVALENCE AND RISK FACTORS FOR CARDIAC IRON OVERLOAD AND CARDIOVASCULAR COMPLICATIONS AMONG PATIENTS WITH THALASSEMIA IN NORTHERN THAILAND.
    Tantiworawit A; Tapanya S; Phrommintikul A; Saekho S; Rattarittamrong E; Norasetthada L; Chai-Adisaksopha C; Hantrakool S; Charoenkwan P; Chattipakorn N
    Southeast Asian J Trop Med Public Health; 2016 Nov; 47(6):1335-42. PubMed ID: 29634199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
    Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
    J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.